These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 22947349

  • 1. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs.
    Rabbiosi S, Peroni E, Tronconi GM, Chiumello G, Losa M, Weber G.
    Thyroid; 2012 Oct; 22(10):1076-9. PubMed ID: 22947349
    [Abstract] [Full Text] [Related]

  • 2. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
    Rimareix F, Grunenwald S, Vezzosi D, Rivière LD, Bennet A, Caron P.
    Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
    Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, Chanson P, Tabarin A, Goth MI, Blumberg J, Catus F, Ispas S, Beck-Peccoz P.
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
    Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, Marechaud R, Teutsch C, Vidal E, Sassano P.
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
    [Abstract] [Full Text] [Related]

  • 5. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
    Iglesias P, Díez JJ.
    J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
    [Abstract] [Full Text] [Related]

  • 6. Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide).
    Caron P, Gerbeau C, Pradayrol L, Simonetta C, Bayard F.
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1164-8. PubMed ID: 8772594
    [Abstract] [Full Text] [Related]

  • 7. A thyrotropin-secreting macroadenoma with positive growth hormone and prolactin immunostaining: A case report and literature review.
    Kuzu F, Bayraktaroğlu T, Zor F, G N BD, Salihoğlu YS, Kalaycı M.
    Niger J Clin Pract; 2015 Mar; 18(5):693-7. PubMed ID: 26096253
    [Abstract] [Full Text] [Related]

  • 8. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
    Yamada S, Fukuhara N, Horiguchi K, Yamaguchi-Okada M, Nishioka H, Takeshita A, Takeuchi Y, Ito J, Inoshita N.
    J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
    [Abstract] [Full Text] [Related]

  • 9. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.
    Yoenem A, Cakyr B, Azal O, Corakcy A, Kutlu M, Oezata M.
    Endocr Regul; 1999 Dec; 33(4):169-74. PubMed ID: 10700085
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Diagnosis and treatment of pituitary adenomas.
    Chanson P, Salenave S.
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [Abstract] [Full Text] [Related]

  • 13. [Somatostatin analogs in the clinical management of pituitary neoplasms].
    Colao A, Dorato M, Pulcrano M, Rossi FW, Auriemma RS, Lombardi G, Lastoria S.
    Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
    [Abstract] [Full Text] [Related]

  • 14. [Thyrotropin--TSH secreting pituitary tumor].
    Zieliński G, Podgórski JK, Warczyńska A, Koziarski A, Zgliczyński W.
    Przegl Lek; 2002 Sep; 59(12):1018-23. PubMed ID: 12731380
    [Abstract] [Full Text] [Related]

  • 15. Preoperative long-acting octreotide treatment for invasive thyrotropin-secreting pituitary macroadenoma after previous radioiodine thyroid ablation.
    Gruszka A, Zielinski GM, Kunert-Radek J.
    J Clin Neurosci; 2014 Feb; 21(2):340-2. PubMed ID: 23958483
    [Abstract] [Full Text] [Related]

  • 16. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
    Sy RA, Bernstein R, Chynn KY, Kourides IA.
    J Clin Endocrinol Metab; 1992 Mar; 74(3):690-4. PubMed ID: 1740506
    [Abstract] [Full Text] [Related]

  • 17. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.
    Wémeau JL, Dewailly D, Leroy R, D'Herbomez M, Mazzuca M, Decoulx M, Jaquet P.
    J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119
    [Abstract] [Full Text] [Related]

  • 18. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
    Nguyen HD, Galitz MS, Mai VQ, Clyde PW, Glister BC, Shakir MK.
    Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
    [Abstract] [Full Text] [Related]

  • 19. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 20. [Thyrotropin-secreting pituitary adenomas].
    Caron P.
    Presse Med; 2009 Jan; 38(1):107-11. PubMed ID: 18980829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.